ML
Matthew Luchini BMO Capital Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Replimune Group
REPL
$474M
| $6.07 | $30 |
394%
upside
| Outperform |
18 Mar ‘22
3 years ago |
|
2
Jasper Therapeutics
JSPR
$42.6M
| $2.62 | $190 |
7,152%
upside
| Outperform |
20 Oct ‘21
3 years ago |
|
3
Apellis Pharmaceuticals
APLS
$3.4B
| $26.92 | $69 |
156%
upside
| Outperform |
10 Sep ‘21
4 years ago |
|
4
Kodiak Sciences
KOD
$521M
| $9.87 | $104 |
954%
upside
| Market Perform |
11 May ‘21
4 years ago |
|
5
C4 Therapeutics
CCCC
$192M
| $2.70 | $55 |
1,937%
upside
| Outperform |
31 Mar ‘21
4 years ago |
|
6
Arvinas
ARVN
$586M
| $7.98 | $101 |
1,166%
upside
| Outperform |
31 Mar ‘21
4 years ago |
|
7
Regeneron Pharmaceuticals
REGN
$58.9B
| $555.94 | $630 |
13%
upside
| Outperform |
25 Jan ‘21
4 years ago |
|
8
Madrigal Pharmaceuticals
MDGL
$10.1B
| $453.55 | $124 |
73%
downside
| Market Perform |
6 Nov ‘20
4 years ago |
|
9
Gilead Sciences
GILD
$144B
| $115.70 | $64 |
45%
downside
| Market Perform |
29 Oct ‘20
4 years ago |
|
10
Viking Therapeutics
VKTX
$2.87B
| $25.55 | $14 |
45%
downside
| Outperform |
5 Jun ‘20
5 years ago |
|